NASDAQ
22.20USD
-1.15 (-4.91%)
We have scored 11 news catalysts on Tango Therapeutics, Inc. (TNGX) over the past 12 months. The biggest single-day move next to one of them came Mar 5, 2026, when TNGX closed +36.3%: “Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact”. Coverage across the window leans positive (average ticker sentiment +0.19). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.7B
P/E
—
EPS
—
Beta
1.17
52W range
7.12-34.39
Day range
22.00–23.95
Open
23.41
Prev close
23.34
Volume
5.4M
Avg volume
3.4M
Dividend
0.00
IPO
2020-09-03
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Tango Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for TNGX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
